Theravance Biopharma (TBPH) Non Operating Investment Income (2025)
Powered by 
Analysis
Theravance Biopharma (TBPH) Non Operating Investment Income (2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.56 Bn | 58.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.22 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.18 Bn | 44.18 Bn | - | - |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.31 Bn | 32.00 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | - |
| 10 | Theravance Biopharma | 882.47 Mn | 494.82 Mn | - | - |